• Exendin-4: Practical Workflows and Innovations for Beta Cell

  2026-07-23

  Exendin-4 is a gold-standard GLP-1 receptor agonist for probing beta cell function and insulin sensitivity in type 2 diabetes research. This article distills advanced workflows, experimental pitfalls, and recent breakthroughs—like stable yeast expression—into actionable guidance for translational scientists.

• GDC-0068 (RG7440) Pan-AKT Inhibitor: Reliable PI3K/Akt/mTOR

  2026-07-23

  This article addresses real-world challenges in cell viability and PI3K/Akt/mTOR pathway research, demonstrating how GDC-0068 (RG7440) Pan-AKT Inhibitor (SKU A3006) from APExBIO offers data-backed solutions for reproducible, selective Akt inhibition. Scenario-driven Q&As guide laboratory scientists through protocol optimization, data interpretation, and informed product selection.

• Exendin-4: Applied Workflows for Insulin Sensitivity Researc

  2026-07-22

  Exendin-4 (Exenatide) empowers type 2 diabetes research by enabling precise modeling of insulin sensitivity improvement and hepatic steatosis reversal. This guide translates bench-proven protocols and recent workflow innovations into actionable steps, troubleshooting advice, and strategic perspectives for advanced beta cell function studies.

• JNK-IN-7: Selective JNK Inhibitor for Apoptosis Pathway Rese

  2026-07-22

  JNK-IN-7 empowers researchers to dissect MAPK and Toll receptor signaling with extraordinary specificity, enabling nuanced analysis of apoptosis and immune pathways. Its covalent selectivity and robust performance position it as an indispensable tool for cell-based kinase assays and mechanistic studies in inflammation and apoptosis.

• A-1331852: Precision BCL-XL Inhibition for Advanced Apoptosi

  2026-07-21

  A-1331852, a highly selective BCL-XL inhibitor from APExBIO, delivers unparalleled potency and specificity for apoptosis assays and targeted cancer research. This guide translates mechanistic advances and workflow optimizations into actionable strategies for robust, reproducible results—addressing both practical setup and troubleshooting for next-generation studies.

• EdU Imaging Kits (Cy5): Advanced S-Phase DNA Synthesis Detec

  2026-07-21

  EdU Imaging Kits (Cy5) unlock high-sensitivity, morphology-preserving measurement of cell proliferation, outperforming legacy BrdU assays for both microscopy and flow cytometry. Explore optimized workflows, troubleshooting tactics, and translational applications in genotoxicity and stem cell research.

• WST-8 Glucose Uptake Assay Kit: Precision in Metabolic Analy

  2026-07-20

  The WST-8 Glucose Uptake Assay Kit streamlines non-radioactive, quantitative measurement of cellular glucose uptake, empowering research in metabolism, diabetes, and cancer. With robust sensitivity, a colorimetric readout, and compatibility with complex metabolic models, this APExBIO solution delivers actionable insights into metabolic dysfunction and therapeutic intervention.

• A20 Modulates Oxidized Self-DNA-Driven Inflammation in AKI

  2026-07-20

  The reference study elucidates how the ubiquitin-editing enzyme A20 attenuates inflammation driven by oxidized self-DNA in acute kidney injury (AKI), primarily by disrupting NLRP3 inflammasome activation via NEK7 interference. These mechanistic insights refine our understanding of inflammation pathways in AKI and offer new avenues for translational intervention targeting sterile inflammatory processes.

• Everolimus (RAD001): Deep Mechanistic Insights for mTOR Path

  2026-07-19

  Explore the advanced mechanistic underpinnings and research protocols of Everolimus (RAD001), a potent mTOR pathway inhibitor. This article offers a unique, evidence-based perspective on optimizing experimental design and interpreting drug responses in cancer research.

• ARID1A Loss Promotes Osimertinib Resistance via PTEN/Akt Axi

  2026-07-18

  The referenced study uncovers a mechanistic link between ARID1A deficiency and acquired resistance to osimertinib in lung adenocarcinoma. By elucidating the epigenetic suppression of PTEN and subsequent Akt pathway activation, the research highlights the ARID1A-PTEN-Akt regulatory axis as a promising target for overcoming therapeutic resistance.

• SmD2 Acetylation and HDAC2 Inhibition Sensitize HCC to PARP

  2026-07-17

  This study identifies acetylation-dependent regulation of the spliceosome core protein SmD2 as a critical mechanism modulating alternative splicing and DNA damage response in hepatocellular carcinoma (HCC). The authors demonstrate that selective HDAC2 inhibition, particularly with Romidepsin (FK228), destabilizes SmD2, synergizing with PARP inhibition to enhance anti-tumor activity, thus highlighting a novel combinatorial therapeutic approach for HCC.

• Meropenem Trihydrate: Mechanisms, Evidence & Research Protoc

  2026-07-17

  Meropenem trihydrate, a carbapenem antibiotic, exhibits potent activity against a broad spectrum of bacteria and is a critical tool in resistance phenotyping. Evidence from recent metabolomics studies validates its efficacy and highlights its role in translational microbiology research.

• Elobixibat Hydrate: Applied Workflows for IBAT Inhibition Re

  2026-07-16

  Elobixibat hydrate stands apart as a precision ileal bile acid transporter inhibitor, enabling robust modulation of enterohepatic circulation for studies in chronic constipation, metabolic regulation, and colonoscopy preparation. This guide details experimental protocols, troubleshooting tactics, and translational insights that maximize reproducibility and impact.

• B. pseudomallei BipD Hijacks Host E3 Ligase to Induce Mitoph

  2026-07-16

  This study reveals how Burkholderia pseudomallei utilizes its BipD protein to hijack the host KLHL9/KLHL13/CUL3 E3 ligase, leading to IMMT ubiquitination and mitophagy initiation. These findings elucidate a novel bacterial survival strategy and highlight the broader relevance of neddylation and E3 ligase regulation in infection biology.

• SHC-1 Inhibition Enhances CFTR Surface Localization in Epith

  2026-07-15

  This study systematically dissects the impact of SHC-1 inhibition on the plasma membrane abundance of CFTR channels across different epithelial cell models. The findings clarify cell-type-specific mechanisms that regulate CFTR trafficking, with implications for cystic fibrosis, COPD, and secretory diarrhea research.

16105 records 1/1074 page Next 12345 下5页 Last page